Objective: To demonstrate, in vitro, the influence of increasing ibuprofen (IBU) concentration on bilirubin-albumin (B-A) binding.
Introduction
Increasing evidence from clinical studies have suggested that ibuprofen (IBU), a nonsteroidal anti-inflammatory drug is effective in the closure of patent ductus arteriosus and prevention of intraventricular hemorrhage. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Published trials have also demonstrated its better safety and tolerability as compared to indomethacin and its possible role in neonatal therapeutics. [11] [12] [13] Since the first report of drug-bilirubin interactions in the pathogenesis of kernicterus, the potential for significant drug-bilirubin interactions has become an important consideration in neonatal drug therapy. [14] [15] [16] [17] All drugs intended for neonatal use should be evaluated for their capacity to displace bilirubin. Thus, investigation for the effect of IBU on bilirubin-albumin binding is therefore warranted. A study by Cooper-Peel et al. 18 showed that free IBU concentrations are increased by the addition of bilirubin by reverse displacement method. Since IBU is displaced by bilirubin or reversibly, bilirubin is displaced by IBU, IBU may therefore increase the risk of bilirubin encephalopathy when used in sick, premature neonates.
The current dose of IBU for patent ductus arteriosus (PDA) closure is started at 10 mg kg À1 per dose followed by 5 mg kg À1 per dose for 2 days, total of three doses in 3 days. This has been shown to achieve an 80% closure rate with minimal adverse effects and has not been shown to induce displacement of bilirubin from albumin. 10 Although no study has yet been reported on the occurrence of kernicterus in low birth weight newborns exposed to IBU, the effect of higher doses of IBU, which could potentially increase PDA closure rates, on bilirubin-albumin binding is not known. The levels of IBU in serum from this recommended dose is from 116 to 180 mg l À1 . 10, 19 In this study, we describe the effect of higher IBU L-lysinate plasma concentration (200 and 285 mg l À1 ) on bilirubin-albumin binding in premature newborn sera and bilirubin-albumin solutions in vitro.
Methods
Serum samples were obtained from a total of 10 premature neonates with gestational age between 27 and 32 weeks and birth weight of 700 to 1400 g. Their bilirubin and albumin concentrations ranged from 5 to 10 mg per 100 ml and 2.4 to 3.0 g per 100 ml, respectively. The influence of IBU on bilirubin-albumin binding was measured in vitro, by saturation index (SI) test 20, 21 and horseradish peroxidase (HRP) assay 22 using infant's serum and bilirubin-albumin solutions. Infant's serum was obtained from discarded blood of jaundiced premature neonates in the clinical pathology laboratory. Bilirubin-albumin solutions were prepared using crystalline human serum albumin and bilirubin to achieve bilirubin concentrations of 5 and 10 mg per 100 ml at bilirubin:albumin molar ratios of 0. 
Saturation index test
The SI test of Odell is an indirect measure of albumin saturation with bilirubin and is determined by the change in spectral absorbance of albumin-bound bilirubin at 460 nm in diluted serum after addition of varying concentrations of IBU or ASA. Spectrophotometric analysis was performed with a Zeiss PMQ II spectrophotometer with a magnetically positioned carriage. Five experiments were performed for the patient's serum samples and B-A solutions at two bilirubin concentrations. A SI of 8% or greater indicates a definite risk for bilirubin encephalopathy whereas SI between 7 and 8% is considered as near risk. 23 
Horseradish peroxidase method
The HRP method is an enzyme assay to measure free bilirubin. Unbound bilirubin is oxidized to colorless compounds by hydrogen peroxide in the presence of horseradish peroxidase. The oxidation of free bilirubin is the rate-limiting step and is proportional to the concentration of the enzyme and the equilibrium concentration of free bilirubin in the sample. In the assay, 25 ml of serum was added to 1 ml of phosphate buffer (pH 7.4) containing IBU in a semimicro cuvette of 10 mm pathlength and absorption was measured at 460 nm. The reaction was initiated by adding 5 ml of 4 mM hydrogen peroxide and 10 ml of horseradish peroxidase. Phosphate buffer was used for the negative control. The unbound bilirubin concentration was calculated from the oxidation velocity of the reaction.
Statistical analysis
Descriptive analysis was performed on continuous measures and comparison of means was done by the Student's t-test for independent samples and by one way analysis of variance with Duncan's post hoc analysis.
Results

Saturation index test
The results of the SI test using bilirubin-albumin solutions are shown in Table 1 ) . In infant sera, however, we did not detect a significant displacement of bilirubin from albumin on all IBU concentrations used, with SI range of 0 to 4.8% as shown in Table 2 .
Horseradish peroxidase assay
The free bilirubin levels (mmol l À1 ) in bilirubin-albumin solutions as measured by HRP assay are shown in Table 3 . Free bilirubin concentrations ranged from 0.0244 to 0.0598 mmol l Effect of ibuprofen on bilirubin-albumin binding MTC Ambat et al and were significantly higher at 10 mg per 100 ml as compared to 5 mg per 100 ml bilirubin concentrations at all B:A ratios (P<0.001, t-test). At 5 mg per 100 ml bilirubin concentrations, free bilirubin concentrations were significantly increased by increasing B:A ratios in all IBU concentrations. In contrast, at 10 mg per 100 ml bilirubin concentration, free bilirubin was not significantly increased with increasing B:A ratios in all IBU concentrations. At same B:A ratios, increasing IBU concentrations did not significantly increase free bilirubin concentrations in both 5 or 10 mg per 100 ml bilirubin concentrations. In the phosphate buffer control, free bilirubin concentrations ranged from 0.005 to 0.050 mmol l À1 . In both 5 and 10 mg per 100 ml bilirubin solutions and at all concentrations of added IBU, the concentrations of free bilirubin were significantly higher (P<0.01) with added IBU as compared to added phosphate buffer (not shown in the table).
Using infant sera, free bilirubin concentrations ranged from 0.019 to 0.069 mmol l À1 after addition of IBU as shown in Table 4 . There was a significantly higher free bilirubin concentration when IBU was added to serum containing 10 mg per 100 ml bilirubin as compared to 5 mg per 100 ml (0.062±0.004 versus 0.026±0.005, P<0.001 by Student' t-test). However, increasing the concentration of IBU did not result in a significant increase in the concentration of free bilirubin in either the serum containing 5 or 10 mg per 100 ml bilirubin.
Discussion
Several studies support the use of IBU as an alternative treatment for PDA in premature infants. IBU has been shown to have similar efficacy as indomethacin in facilitating ductal closure with less adverse effects. These comparative trials however have focused mainly on the mesenteric and renal blood flow changes and cerebral hemodynamics. Only one study has documented the effect of IBU on bilirubin-albumin binding in newborn infant serum in vitro.
This study, using HRP assay, has demonstrated that IBU at plasma concentrations of 142.5 mg l À1 and greater causes an increase in free bilirubin levels as compared to phosphate buffer, in both infant sera and bilirubin-albumin solutions. However, free bilirubin levels were not significantly increased by increasing the IBU concentrations. Higher free bilirubin concentrations were found with the addition of IBU at 10 versus 5 mg per 100 ml bilirubin solution at all B:A ratios and IBU concentrations, indicating the important role of serum bilirubin concentration in determining the amount of free bilirubin. The protective role of bilirubin albumin ratio was observed only at low concentrations of bilirubin in solution. At 5 mg per 100 ml, free bilirubin was significantly increased by the addition of IBU only at B:A ratio of 1 or greater). However, at 10 mg per 100 ml, free bilirubin concentrations were not significantly different whether at B:A ratio of 0.5 or 2.0. In contrast, by the SI test using bilirubin-albumin solutions, displacement of bilirubin from albumin was seen only at B:A ratio of 2.0 and IBU concentration of 285 mg l À1 . This same result was not exhibited in infant sera. This may be due to the lower B:A ratio of our serum samples which ranged from 0.2 to 0.5.
The discrepancy between the results of the SI and HRP tests may be that each test measures a slightly different aspect of bilirubin-albumin binding. The first few studies on bilirubin-albumin binding tests reported only low orders of correlation between tests, and currently there are no available information on the correlation between SI test and free bilirubin measurement.
Although the neurotoxic concentration of free bilirubin is not precisely known and may vary under different clinical conditions, experimental and clinical evidences indicate that the free bilirubin concentration is probably the most critical parameter in establishing the risk for bilirubin encephalopathy. Although none of the published trials have reported bilirubin encephalopathy, this study indicates that the issue of bilirubinFalbumin-IBU interactions is far from resolved. However, it is encouraging to note that free bilirubin is not increased in newborns treated with IBU as reported by van Overmiere et al. 24 Free or unbound bilirubin were measured in 15 preterm neonates with birth weight of 1210 g (s.d. 55.0), gestational age of 28.4 weeks (s.d. 3.1) and age of 4.2 days. The free bilirubin levels did not change before and after IBU infusion (10-5-5 mg kg À1 per dose) (1.07 versus 1.00 mg per 100 ml, P ¼ NS).
In this study, we determined that IBU concentrations above the normal plasma levels achieved with clinical dosing and a high B:A ratio of 2 have the potential to cause displacement of bilirubin from albumin as measured by the SI test. By the HRP assay, IBU at therapeutic concentration (142.5 mg l À1 ) caused an increase in free bilirubin levels as compared to phosphate buffer. Increasing the IBU concentration beyond the therapeutic range increased the free bilirubin levels but not significantly higher than that achieved using IBU concentration within the therapeutic range. This suggests that higher doses of IBU can be used without significant increase in free bilirubin concentrations.
Further studies to resolve this issue is warranted to assure safety of this drug in preterm newborns with hyperbilirubinemia.
